Staar Surgical CO 8-K filings

STAAR Surgical's Q4 and fiscal year 2024 results were impacted by weak macroeconomic conditions in China, overshadowing growth in other regions, and the company anticipates lower demand in China for fiscal year 2025.

STAAR Surgical will release its Q4 and fiscal year 2024 financial results on February 19, 2025, after market close, and will host a webcast to discuss the results and 2025 outlook.

STAAR Surgical updated its financial outlook for fiscal year 2024, adjusting APAC regional growth assumptions while reaffirming its overall net sales guidance of $340 million to $345 million.

STAAR Surgical announced a 10% increase in net sales to $88.6 million for the third quarter of 2024, fueled by growth in all regions and strong adoption of its EVO ICL lenses.

STAAR Surgical reported record quarterly net sales of $99.0 million, or $100.4 million in constant currency, and raised its fiscal year 2024 net sales and adjusted EBITDA outlook.

STAAR Surgical Company's shareholders approved an amendment to the company's equity incentive plan, increasing the number of shares available for issuance by 2.6 million at the 2024 Annual Meeting.

STAAR Surgical's investor presentation highlights strong first-quarter growth, increased market share for its EVO ICL product, and a positive outlook for future expansion.

STAAR Surgical reported a 5% increase in net sales for Q1 2024, driven by a 9% rise in ICL sales, but experienced a net loss compared to the previous year's profit.

STAAR Surgical reports preliminary Q1 2024 net sales exceeding $77 million, highlighted by record U.S. ICL sales of $5 million.

STAAR Surgical announces the sale of over three million Implantable Collamer Lenses (ICLs) globally, marking a significant milestone in their vision correction technology.

STAAR Surgical has appointed Arthur Butcher and Wei Jiang to its Board of Directors, while also announcing that K. Peony Yu will not seek re-election.

STAAR Surgical reported strong net sales, cash generation, and profitability for 2023, with global ICL unit growth exceeding refractive industry growth by over 25 points.

STAAR Surgical reported a 19% increase in net sales for the fourth quarter of 2023, driven by a 22% surge in ICL sales, and affirms its 2024 sales outlook.